Issa F. Khouri

20.0k total citations · 2 hit papers
297 papers, 12.5k citations indexed

About

Issa F. Khouri is a scholar working on Hematology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Issa F. Khouri has authored 297 papers receiving a total of 12.5k indexed citations (citations by other indexed papers that have themselves been cited), including 200 papers in Hematology, 115 papers in Pathology and Forensic Medicine and 107 papers in Oncology. Recurrent topics in Issa F. Khouri's work include Hematopoietic Stem Cell Transplantation (135 papers), Lymphoma Diagnosis and Treatment (111 papers) and Chronic Lymphocytic Leukemia Research (92 papers). Issa F. Khouri is often cited by papers focused on Hematopoietic Stem Cell Transplantation (135 papers), Lymphoma Diagnosis and Treatment (111 papers) and Chronic Lymphocytic Leukemia Research (92 papers). Issa F. Khouri collaborates with scholars based in United States, United Kingdom and Australia. Issa F. Khouri's co-authors include Richard E. Champlin, Sergio Giralt, Paolo Anderlini, Börje S. Andersson, James Gajewski, Donna Przepiorka, Rima M. Saliba, Chitra Hosing, Naoto T. Ueno and David F. Claxton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Issa F. Khouri

287 papers receiving 12.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

1997 909 citations Sergio Giralt, Koen van Besien et al. Blood profile →
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

1998 738 citations Issa F. Khouri, Michael J. Keating et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Issa F. Khouri United States	60	8.2k	4.3k	4.0k	3.6k	3.3k	297	12.5k
Paolo Anderlini United States	49	7.5k 0.9×	3.4k 0.8×	3.1k 0.8×	1.8k 0.5×	2.1k 0.6×	210	10.3k
Thomas R. Chauncey United States	50	7.8k 0.9×	2.7k 0.6×	2.7k 0.7×	1.0k 0.3×	2.2k 0.7×	167	9.6k
James Gajewski United States	48	7.8k 0.9×	2.8k 0.7×	3.2k 0.8×	1.1k 0.3×	1.6k 0.5×	131	9.9k
Chitra Hosing United States	51	5.1k 0.6×	3.2k 0.8×	2.2k 0.5×	1.8k 0.5×	1.5k 0.5×	372	8.9k
Norbert Schmitz Germany	69	5.8k 0.7×	8.3k 2.0×	3.9k 1.0×	10.1k 2.8×	4.7k 1.4×	397	17.1k
FR Appelbaum United States	63	9.3k 1.1×	3.4k 0.8×	3.4k 0.9×	683 0.2×	2.0k 0.6×	189	12.4k
Anthony H. Goldstone United Kingdom	60	10.6k 1.3×	4.6k 1.1×	1.9k 0.5×	3.6k 1.0×	2.9k 0.9×	202	15.7k
Benedetto Bruno Italy	51	5.5k 0.7×	2.6k 0.6×	2.1k 0.5×	843 0.2×	1.3k 0.4×	278	8.0k
Auayporn Nademanee United States	39	3.1k 0.4×	3.3k 0.8×	1.3k 0.3×	3.2k 0.9×	1.3k 0.4×	180	7.3k
Guillermo Sanz Spain	48	12.4k 1.5×	2.4k 0.6×	1.8k 0.4×	1.1k 0.3×	4.6k 1.4×	292	14.7k

Countries citing papers authored by Issa F. Khouri

Since Specialization

Citations

This map shows the geographic impact of Issa F. Khouri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Issa F. Khouri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Issa F. Khouri more than expected).

Fields of papers citing papers by Issa F. Khouri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Issa F. Khouri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Issa F. Khouri. The network helps show where Issa F. Khouri may publish in the future.

Co-authorship network of co-authors of Issa F. Khouri

This figure shows the co-authorship network connecting the top 25 collaborators of Issa F. Khouri. A scholar is included among the top collaborators of Issa F. Khouri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Issa F. Khouri. Issa F. Khouri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharma, Padmanee, Denái R. Milton, Alison Gulbis, et al.. (2025). Long-Term Results of Ipilimumab Alternating with Lenalidomide in Patients with Relapsed Lymphoma Who Underwent Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 31(2). S427–S428.

Ledesma, Celina, Nitin Jain, Priti Tewari, et al.. (2024). Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 2810–2810. 1 indexed citations

Al‐Juhaishi, Taha, Yingjun Wang, Denái R. Milton, et al.. (2023). Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplantation. 58(9). 1000–1007. 3 indexed citations

Jabbour, Elias, Koji Sasaki, Fadi Haddad, et al.. (2023). The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors. American Journal of Hematology. 98(4). 658–665. 15 indexed citations

Kantarjian, Hagop M., Nicholas J. Short, Nitin Jain, et al.. (2023). Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results. American Journal of Hematology. 98(3). 493–501. 45 indexed citations

Chahoud, Jad, Dawen Sui, William D. Erwin, et al.. (2018). Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clinical Cancer Research. 24(10). 2304–2311. 8 indexed citations

Rezvani, Katayoun, Betül Oran, Rohtesh S. Mehta, et al.. (2018). Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation. 25(3). 505–514. 14 indexed citations

Khouri, Issa F., Elias Jabbour, Celina Ledesma, et al.. (2017). Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results. Blood. 130. 2036–2036. 1 indexed citations

Khouri, Issa F., Alison Gulbis, Denái R. Milton, et al.. (2017). Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies. Blood. 130. 3240–3240.

10.

Kröger, Nicolaus, Ulrike Bacher, Peter Bader, et al.. (2010). NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation. 16(9). 1187–1211. 60 indexed citations

11.

Khouri, Issa F., Peter McLaughlin, Rima M. Saliba, et al.. (2008). Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 111(12). 5530–5536. 215 indexed citations

12.

Westin, Jason R., Rima M. Saliba, Marcos de Lima, et al.. (2007). Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).. Blood. 110(11). 5015–5015. 1 indexed citations

13.

Rodriguez, Maria Alma, Koen van Besien, Fredrick B. Hagemeister, et al.. (2003). Randomized comparison of frontline alternating chemotherapy versus brief induction followed by autologous stem cell transplant for aggressive lymphomas. Blood. 102(11). 40216. 2 indexed citations

14.

Champlin, Richard E., Issa F. Khouri, Paolo Anderlini, et al.. (2001). Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplantation. 27(S2). S13–S22. 37 indexed citations

15.

Khouri, Issa F., Mark F. Munsell, Susan O’Brien, et al.. (2000). Comparable survival for nonablative and ablative allogeneic transplantation for chronic lymphocytic leukemia (CLL): The case for early intervention. Blood. 96. 13 indexed citations

16.

Champlin, Richard E., Issa F. Khouri, Avichai Shimoni, et al.. (2000). Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. British Journal of Haematology. 111(1). 18–29. 157 indexed citations

17.

Champlin, Richard, Issa F. Khouri, & Sergio Giralt. (1999). Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: Induction of graft-vs.-malignancy as treatment for malignant diseases. Journal of Clinical Apheresis. 14(1). 45–49. 5 indexed citations

18.

Khouri, Issa F., et al.. (1996). Fludarabine (famp)-based chemotherapy at conventional doses allows engraftment of allogeneic (allo) peripheral blood progenitor cell (pbpc) transplantation in chronic lymphocytic leukemia (cll). Experimental Hematology. 24(9). 1 indexed citations

19.

Besien, Koen van, Rakesh Mehra, Sergio Giralt, et al.. (1996). Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology. The American Journal of Medicine. 100(3). 299–307. 87 indexed citations

20.

Khouri, Issa F., Hagop M. Kantarjian, Moshe Talpaz, et al.. (1996). Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience.. PubMed. 17(5). 775–9. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact